Fiche centre
Hospital Universitari i Politècnic La Fe
Valencia — Spain
Essais liés24clinical trials
VilleValencialocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07571200
Essais cliniques associés
24| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Prasinezumab | Parkinson | Phase 2 | NCT04777331 | PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| Ozanimod | SEP | Phase 3 | NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | RECRUITING |
| Emapalumab | Lupus | Phase 3 | NCT05001737 | EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | COMPLETED |
| DRALEGA — A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain | Épilepsie | À vérifier | NCT05982717 | DRALEGA — A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain | COMPLETED |
| Elranatamab | Cancer | Phase 3 | NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING |
| Inotuzumab ozogamicin | Cancer | Phase 2 | NCT05748171 | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | RECRUITING |
| LY4256984 | Sclérose latérale amyotrophique | Phase 1 | NCT07571200 | A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) | RECRUITING |
| LY4256984 | Sclérose latérale amyotrophique | Phase 1 | NCT07571174 | A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | RECRUITING |
| Pridopidine | Sclérose latérale amyotrophique | Phase 3 | NCT07322003 | PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | RECRUITING |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | RECRUITING |
| Pozelimab + Cemdisiran | Myasthénie | Phase 3 | NCT05070858 | NIMBLE — A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Inebilizumab | Myasthénie | Phase 2 | NCT06987539 | THYME — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) | RECRUITING |
| CC-97540 | Myasthénie | Phase 1 | NCT06220201 | A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | ACTIVE_NOT_RECRUITING |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | ACTIVE_NOT_RECRUITING |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| Obecabtagene autoleucel (obe-cel) | Lupus | Phase 1 | NCT06333483 | CARLYSLE — Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04252742 | EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine | COMPLETED |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03836040 | OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT06616194 | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | ACTIVE_NOT_RECRUITING |
| MEDI0618 | Migraine | Phase 2 | NCT06602479 | AURORA — A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | RECRUITING |
| Pegcetacoplan (APL-2) | Sclérose latérale amyotrophique | Phase 2 | NCT04579666 | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | TERMINATED |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |